Floatz logo

Cediranib

Plasma Cell Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Plasma Cell Neoplasm cohort.

Asset / SponsorPhaseRating
cc-5013
Hellenic Society of Hematology
Phase 3BBB
Cyclophosphamide
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
Fludarabine
Affiliated Hospital to Academy of Military Medical Sciences
Phase 3BB
FILGRASTIM
Hellenic Society of Hematology
Phase 3BB
METHOTREXATE
Masonic Cancer Center, University of Minnesota
Phase 2BB

View all 35 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →